Headache · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher headache ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
1 finding from 1 review
Treatment discontinuation · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in treatment discontinuation compared with cidofovir (moderate certainty).
1 finding from 1 review
Intervention not reported
Surgical excision versus laser vaporisationor other · women with usual‐type vulval intraepithelial neoplasia
1 finding from 1 review
Intervention not reported
Laser vaporisation versus CUSA · women with usual‐type vulval intraepithelial neoplasia
The intervention showed no clear difference in laser vaporisation versus CUSA (low certainty).
1 finding from 1 review
Intervention not reported
Photodynamic therapy versus laser vaporisationand surgical excision · women with usual‐type vulval intraepithelial neoplasia
1 finding from 1 review
Intervention not reported
LEEP versus laser vaporisation and surgical excision · women with usual‐type vulval intraepithelial neoplasia
1 finding from 1 review
Complete response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ complete response compared with placebo (high certainty).
2 findings from 1 review
Response to treatment at 12 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher response to treatment at 12 months ‐ overall response compared with placebo (moderate certainty).
1 finding from 1 review
Progression to vulval cancer at 12 months · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in progression to vulval cancer at 12 months compared with placebo (low certainty).
1 finding from 1 review
HPV DNA persistence · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to lower HPV DNA persistence compared with placebo (high certainty).
1 finding from 1 review
Pain ‐ Any grade · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher pain ‐ any grade compared with placebo (high certainty).
1 finding from 1 review
Dose reductions · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher dose reductions compared with placebo (high certainty).
1 finding from 1 review
Response to treatment at 6 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in response to treatment at 6 months ‐ overall response compared with cidofovir (moderate certainty).
1 finding from 1 review
Intervention not reported
Overall 5‐year survival1 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
1008 participants
High
Intervention not reported
Progression‐free 5‐year survival2 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
1170 participants
High
Intervention not reported
Overall 10‐year3 survival · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
925 participants
High
Intervention not reported
Progression‐free 10‐year survival4 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
925 participants
High
Intervention not reported
Adverse events · women with stage I/II epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality up to 30 days · people with neutropenia or neutrophil dysfunction
It is very uncertain whether the intervention changes all‐cause mortality up to 30 days (very low certainty).
1 finding from 1 review